Please login to the form below

Not currently logged in
Email:
Password:

Chase adds former Allergan execs to leadership team

Scott Giacobello and Gary Charbonneau join

Chase Pharmaceuticals Scott GiacobelloCalifornian Chase Pharmaceuticals has made two appointments to its senior leadership team.

Scott Giacobello (pictured right) becomes chief financial officer at the clinical-stage biopharma company, bringing almost 25 years of experience in finance and accounting.

Most recently, Giacobello served as vice president of finance for global research and development at Allergan, and has held financial positions at Black & Decker and Ernst & Young.

Meanwhile, Gary Charbonneau (pictured below) has been appointed as senior vice president for regulatory affairs and operations.

Charbonneau joins Chase with over 25 years of experience in regulatory, quality and research and development operations.

He moves from Allergan, where he spent 14 years in a number of senior regulatory positions, including his most recent role as vice president of international regulatory affairs.

Chase Pharmaceuticals Gary CharbonneauCharbonneau also brings experience from Amgen, Baxter, Novo Nordisk and Roche

Douglas Ingram, chief executive officer at Chase, said: “I could not be more delighted to welcome Scott and Gary to Chase.

“With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease.

“Scott and Gary have the proven track records, enthusiasm and commitment to operational excellence that will help Chase succeed in improving the lives of millions of patients suffering from this devastating disease.”

20th June 2016

From: Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...